Insider Emily McGinnis plans 901-share TSHA sale under Rule 144

Rhea-AI Filing Summary

Taysha Gene Therapies insider files to sell shares under Rule 144. Emily McGinnis filed a notice to sell 901 shares of Taysha Gene Therapies common stock through Maxim Group LLC on or about 02/04/2026 on Nasdaq. These 901 shares were acquired on 02/03/2026 via an RSU award that vested and settled in stock as compensation for continued employment.

The notice reports that 273,919,373 shares of common stock were outstanding. Over the prior three months, McGinnis sold 25,119 shares for gross proceeds of $119,315.25 and 7,586 shares for $34,971.46. By signing, the seller represents not knowing any undisclosed material adverse information about the company.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	901	4252.72	273919373	02/04/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/03/2026	RSU Award	Issuer			901	02/03/2026	Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Emily McGinnis c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/23/2026	25119	119315.25
Emily McGinnis c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/26/2026	7586	34971.46

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TSHA Form 144 filing by Emily McGinnis disclose?

The filing discloses a planned sale of 901 TSHA shares under Rule 144. Emily McGinnis intends to sell 901 shares of Taysha Gene Therapies common stock through Maxim Group LLC on Nasdaq, following acquisition via a vested RSU award on February 3, 2026.

How many Taysha Gene Therapies (TSHA) shares are covered by this Form 144?

The notice covers a proposed sale of 901 common shares. These 901 shares were obtained through an RSU award that vested and settled in stock on February 3, 2026, and are planned for sale on or about February 4, 2026 via Nasdaq.

How many TSHA shares were outstanding when this Form 144 was filed?

The filing reports 273,919,373 TSHA common shares outstanding. This figure provides context for the relative size of the planned 901-share sale and prior sales by the same insider during the three months preceding the notice.

What prior TSHA stock sales by Emily McGinnis are disclosed in the Form 144?

The notice lists two prior TSHA stock sales in the last three months. McGinnis sold 25,119 shares on January 23, 2026 for $119,315.25 and 7,586 shares on January 26, 2026 for $34,971.46, all in Taysha Gene Therapies common stock.

How were the TSHA shares in the Form 144 acquired by the insider?

The 901 TSHA shares were acquired via a restricted stock unit award. The RSU award vested and was settled in stock on February 3, 2026, with consideration described as the reporting person’s continued service as an employee of Taysha Gene Therapies.

Which broker will handle the planned TSHA share sale under this Form 144?

Maxim Group LLC is listed as the broker for the sale. The filing states that the 901 Taysha Gene Therapies common shares are to be sold through Maxim Group LLC, with the planned transaction to occur on the Nasdaq stock market.